Abstract
Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal)2), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO4), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate (VO(acac)2) were investigated using several tumor cell lines: mouse fibrosarcoma (L929), rat pheochromocytoma (PC12), human liver carcinoma (HepG2), mouse embryonic fibroblasts (NIH/3T3), and also normal human skin fibroblasts. The results showed that VO(mal)2 effectively inhibited growth of cancer cell cultures without any toxic effect on normal human skin fibroblasts. The cytotoxic anticancer effect of vanadium complexes depended on concentration of the compounds studied, incubation time, types of cell cultures, and nature of ligands surrounding the central group of the complex (VO2+). These studies provide evidence that VO(mal)2 may be considered as a potential anticancer agent due to its low toxicity for non-tumor cells and significant anticancer activity.
Similar content being viewed by others
References
Amir, S., Meyerovich, J., and Shechter, Y., Brain Res., 1987, vol. 419, pp. 392–397.
Brichard, S.M., Bailey, C.J., and Henquin, J.C., Diabetes, 1990, vol. 11, pp. 1126–1132.
Shechter, Y., Diabetes, 1990, vol. 39, pp. 1–5.
Badmaev, V., Prakash, S., and Majeed, M., J. Alternat. Complement. Medicine, 1999, vol. 5, pp. 273–291.
Orvig, C., Thompson, K.H., Battel, M., and McNeill, J.H., Met. Ions Biol. Syst., 1995, vol. 31, pp. 575–594.
Fu, Y., Wang, Q., Yang, X.G., Yang, X.D., and Wang, K., J. Biol. Inorg. Chem., 2008, vol. 13, pp. 1001–1009.
Crans, D., J. Inorg. Biochem., 2000, vol. 80, pp. 123–131.
Crans, D.C., Smee, J.J., Gaidamauskas, E., and Yang, L., Chem. Rev., 2004, vol. 104, pp. 849–942.
Thompson, K.H. and Orvig, C., Dalton Trans., 2006, pp. 761–764.
Bishayee, A., Oinam, S., Basu, M., and Chatterjiee, M., Breast Cancer Res. Treatment, 2000, vol. 63, pp. 133–145.
Evangelou, A.M., Crit. Rev. Oncol./Hematol., 2002, vol. 42, pp. 249–265.
Desoize, B., Anticancer Res., 2004, vol. 24, pp. 1529–1544.
Holko, P., Ligesa, J., Kisilewska, J., Kordowiak, A.M., and Klein, A., Pol. J. Patol., 2008, vol. 59, pp. 3–8.
Etcheverry, S.B., Ferrer, E.G., Naso, L., Rivadeneira, J., Salinas, V., and Williams, P.A., J. Biol. Inorg. Chem., 2008, vol. 13, pp. 435–447.
Faneca, H., Figueiredo, V.A., Tomaz, I., Gonçalves, G., Avecilla, F., Pedroso de Lima, M.C., Geraldes, C.F., Pessoa, J.C., and Castro, M.M., J. Inorg. Biochem., 2009, vol. 103, pp. 601–608.
Thompson, H.J., Chasteen, N.D., and Meeker, L.D., Carcinogenes, 1984, vol. 5, pp. 849–851.
El-Naggar, M.M., El-Waseef, A.M., El-Halafawy, K.M., and El-Sayed, I.H., Cancer Lett., 1998, vol. 133, pp. 71–76.
Osin-ska-Królicka, I., Podsiad’y, H., Bukietyńska, K., Zemanek-Zboch, M., Nowak, D., Suchoszekukaniuk, K., and Malicka-B’aszkiewicz, M., J. Inorg. Biochem., 2004, vol. 98, pp. 2087–2098.
Liasko, R., Kabanos, T.A., Karkabounas, S., Malamas, M., Tasiopoulos, A.J., Stefanou, D., Collery, P., and Evangelou, A., Anticancer Res., 1998, vol. 18(5A), pp. 3609–3613.
Kopf-Maler, P., Eur. J. Clin. Pharmacol., 1994, vol. 47, pp. 1–16.
Belyaeva, N.F., Gorodetskii, V.K., Tochilkin, A.I., Golubev, M.A., Semenova, N.V., and Kovelman, I.R., Vopr. Med. Khim., 2000, vol. 46, pp. 344–360.
Gorodetskii, V.K., Tochilkin, A.I., Belyaeva, N.F., Kovelman, I.R., and Korovkin, B.F., Biomed. Khim., 2011, vol. 57, pp. 133–137.
Tochilkin, A.I., Belyaeva, N.F., Abakumova, O.Yu., and Podobed, O.V., Rus. Patent 2376020, 2009.
Teixeira, M.H.S.F., Costa Pessoa, J., and Vilas Boas, L.F., Polyhedron, 1992, vol. 11, pp. 697–708.
Abakumova, O.Yu, Podobed, O.V., Borisova, A.A., Sidoruk, K.V., Alexandrova, S.S., Omelyanuk, N.M., Pokrovskaya, M.V., Kondakova, L.I., and Sokolov, N.N., Biochemistry (Moscow) Supplement B: Biomedical Chemistry, 2009, vol. 3, pp. 198–201.
Sakurai, H., Tsuchiya, K., Nukatsuka, M., et al., J. Endocrinol., 1990, vol. 126, pp. 451–459.
Sakurai, H., Tamura, H., and Okatani, K., Biochim. Biophys. Res. Commun., 1995, vol. 206, pp.133–137.
Stern, A., Yin, X., Tsang, S.S., Davison, A., and Moon, J., Biochem. Cell. Biol., 1993, vol. 71, pp. 103–112.
Morinville, A., Maysinger, D., and Shaver, A., Trends Pharmacol. Sci., 1998, vol. 19, pp. 452–460.
Wang, Q., Liu, T.-T., Fu, Y., Wang, K., and Yang, X.-G., J. Biol. Inorg. Chem., 2010, vol. 15, pp. 1087–1097.
Ray, R.S., Basu, M., Ghosh, B., Samanta, K., and Chatterjee, M., Nutr. Cancer., 2005, vol. 51, pp. 184–196.
Ray, R.S., Rana, B., Swami, B., Venu, V., and Chatterjee, M., Chem. Biol. Interact., 2006, vol. 163, pp. 239–247.
Kostova, I., Anticancer Agents Med. Chem., 2009, vol. 9, pp. 827–842.
Bishayee, A., Waghray, A., Patel, M.A., and Chatterjee, M., Cancer Lett., 2010, vol. 294, pp. 1–12.
Cruz, O.J.D. and Uckun, F.M., Expert Opin. Investig. Drugs, 2002, vol. 11, pp. 1829–1836.
Narla, R.K., Dong, Y., D’Cruz, O.J., Navara, C., and Uckun, F.M., Clin. Cancer. Res., 2000, vol. 6, pp. 1546–1556.
Chakraborty, T., Samanta, S., Ghosh, B., Thirumoorthy, N., Chatterjee, M., J. Cell. Biochem., 2005, vol. 94, pp. 744–762.
Chen, D., Milacic, V., Frezza, M., and Dou, Q.P., Curr. Pharm. Des., 2009, vol. 15, pp. 777–791.
Yuen, V.G., Orvig, C., Tompson, K.H., and McNeill, J.H., Can. J. Physiol. Pharmacol., 1993, vol. 71, pp. 270–276.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © O.Yu. Abakumova, O.V. Podobed, N.F. Belayeva, A.I. Tochilkin, 2012, published in Biomeditsinskaya Khimiya.
Rights and permissions
About this article
Cite this article
Abakumova, O.Y., Podobed, O.V., Belayeva, N.F. et al. Anticancer activity of oxovanadium compounds. Biochem. Moscow Suppl. Ser. B 6, 164–170 (2012). https://doi.org/10.1134/S1990750812020023
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750812020023